Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (BPMC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,990,281
  • Shares Outstanding, K 49,202
  • Annual Sales, $ 44,520 K
  • Annual Income, $ -236,640 K
  • 60-Month Beta 1.62
  • Price/Sales 235.62
  • Price/Cash Flow N/A
  • Price/Book 7.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.74
  • Number of Estimates 10
  • High Estimate -1.42
  • Low Estimate -2.35
  • Prior Year -1.83
  • Growth Rate Est. (year over year) +4.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.09 +9.46%
on 01/13/20
87.43 -7.24%
on 01/10/20
+5.10 (+6.71%)
since 12/17/19
3-Month
65.67 +23.50%
on 10/30/19
87.43 -7.24%
on 01/10/20
+6.31 (+8.44%)
since 10/17/19
52-Week
65.40 +24.01%
on 01/23/19
102.98 -21.25%
on 07/25/19
+13.86 (+20.61%)
since 01/17/19

Most Recent Stories

More News
PANTHERx® Rare Pharmacy Selected by Blueprint Medicines Corporation to Distribute AYVAKIT(TM) (avapritinib) for Genomically Defined Patient Population with Rare Cancer, GIST

PANTHERx® Rare Pharmacy announces that it has been selected by Blueprint Medicines Corporation as a very limited distribution partner for breakthrough drug AYVAKIT(TM) (avapritinib). It has been approved...

BPMC : 81.10 (+0.17%)
Blueprint Medicines Announces 2020 Corporate Goals

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced corporate goals for 2020, which...

BPMC : 81.10 (+0.17%)
Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer

Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).

BAYRY : 20.9350 (-0.21%)
RHHBY : 42.4200 (+1.60%)
EBS : 55.56 (-0.86%)
BPMC : 81.10 (+0.17%)
Blueprint Medicines Announces FDA Approval of AYVAKIT(TM) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration...

BPMC : 81.10 (+0.17%)
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.

MRK : 90.97 (-0.23%)
RHHBY : 42.4200 (+1.60%)
EBS : 55.56 (-0.86%)
BPMC : 81.10 (+0.17%)
Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced independent centrally reviewed...

FSNN : 0.0580 (-19.44%)
BPMC : 81.10 (+0.17%)
Blueprint Medicines Initiates Dosing in Liver Cancer Study

Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.

RHHBY : 42.4200 (+1.60%)
PBYI : 9.73 (+9.39%)
BPMC : 81.10 (+0.17%)
EPZM : 26.72 (+4.62%)
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company focused on developing and commercializing immuno-oncology and precision medicines, and Blueprint Medicines Corporation (NASDAQ:...

BPMC : 81.10 (+0.17%)
Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why

Blueprint Medicines' (BPMC) NDA for avapritinib to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) and fourth-line GIST is under FDA review. Other pipeline candidates also advance.

BAYRY : 20.9350 (-0.21%)
RHHBY : 42.4200 (+1.60%)
ANIK : 45.43 (-3.57%)
BPMC : 81.10 (+0.17%)
Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor

Lilly (LLY) initiates a phase III study on its oral RET inhibitor, selpercatinib, in treatment-naive, RET fusion-positive NSCLC patients.

GSK : 47.89 (+1.55%)
LLY : 139.58 (-1.31%)
MRK : 90.97 (-0.23%)
BPMC : 81.10 (+0.17%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade BPMC with:

Business Summary

Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.

See More

Key Turning Points

2nd Resistance Point 82.59
1st Resistance Point 81.85
Last Price 81.10
1st Support Level 80.01
2nd Support Level 78.91

See More

52-Week High 102.98
Fibonacci 61.8% 88.62
Fibonacci 50% 84.19
Last Price 81.10
Fibonacci 38.2% 79.76
52-Week Low 65.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar